SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGMED - GenoMed Inc.


Previous 10 Next 10 
To: Tadsamillionaire who wrote (317)10/13/2006 9:53:26 PM
From: jmhollen
   of 347
 
10-4.

Somebody in the AMA 'good ol' boys' network must really have it in for him, but eventually the 'cures' will outweigh the averice.

John :-)

.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (318)11/5/2006 1:36:11 PM
From: Tadsamillionaire
   of 347
 
Annals Publishes GenoMed's Approach to Avian Influenza
GenoMed(TM) (OTC Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today that its approach to avian influenza ("bird flu") has been published by the prestigious journal Annals of Internal Medicine.
October 24, 2006 - 10:12 AM EST
(http://www.annals.org/cgi/eletters/145/8/631#3964).

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "GenoMed is honored to have created a debate within the virology community about whether it's the viral load or the 'cytokine storm' which kills a patient with a lethal viral disease like avian influenza. Three years ago we applied for a patent saying that the 'cytokine storm' alone was lethal, and that the viral load could essentially be ignored. Two years ago, we published that our purely anti-inflammatory approach appears to work for another lethal viral disease, West Nile virus encephalitis."

Dr. Moskowitz continued, "We're eager to keep testing this hypothesis. If we're right, it will transform the way viral diseases are treated in the general population."

Added Dr. Moskowitz, "At this point, as with the rest of our treatments, the only element missing is public awareness. We're reminded every day that if people with viral disease, high blood pressure, diabetes, or emphysema only knew about us, we might be able to help save their lives."

About GenoMed

GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including avian influenza. GenoMed estimates that it can already save 10% of healthcare costs and extend life by several years. The company is currently trying to publicize its intellectual property, since having cures is useless if nobody knows about them.

Share RecommendKeepReplyMark as Last Read


From: Gary Mohilner11/29/2006 2:05:21 AM
   of 347
 
I'm no expert, but does the information in the following post agree with what Dr. M has been saying for some time.

Message 23051621

I wonder if he knows about this.

Gary

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Gary Mohilner who wrote (320)12/1/2006 9:15:45 PM
From: Tadsamillionaire
   of 347
 
Probably Not! EOM.

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire12/12/2006 12:43:06 PM
   of 347
 
Philadelphia Group Confirms GenoMed's Approach to Pancreatic Cancer
GenoMed(TM) (Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today that its published approach to cancer has recently received support from a group at Thomas Jefferson University in Philadelphia.

Dr. Hwyda Arafat at the Kimmel Cancer Center at Thomas Jefferson University recently showed that angiotensin I-converting enzyme (ACE) was active in tumors from patients with pancreatic cancer, and that ACE inhibitors and angiotensin II receptor blockers (ARBs) blocked the production of a potent angiogenesis factor called VEGF in pancreatic cancer cell lines. She suggested that ACE inhibitors and ARBs might be useful in treating pancreatic cancer patients.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Our work, published four years ago, demonstrated that ACE inhibitors and ARBs may work against all but a few cancers. In fact, two years ago we published a case report of a woman with stage IV unresectable pancreatic cancer who lived an extra 14 months using our approach."

Added Dr. Moskowitz, "We're delighted for others to confirm our work again, but if people with cancer, sickle cell disease, viral disease, high blood pressure, diabetes, kidney failure, or emphysema only knew about us, we might be able to help save their lives. At this point, as with the rest of our treatments, the only element missing is public awareness."

About GenoMed

GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure. GenoMed estimates that it can already save 10% of healthcare costs and extend life by several years. The company is currently trying to publicize its intellectual property, since having cures is useless if nobody knows about them.

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire12/20/2006 12:19:34 PM
   of 347
 
ACP Observer Publishes Letter on GenoMed's Ability to Prevent Most Kidney Failure
GenoMed(TM) (Pink Sheets:GMED), a Next Generation Disease Management company, announced today that ACP Observer, the monthly news magazine for doctors of internal medicine published by the American College of Physicians, included a letter in its December issue referring to GenoMed's ability to prevent potentially most kidney failure in the US.

The letter, entitled "Promoting Dialysis Alternative" (http://www.acponline.org/journals/news/dec06/letters.htm), was written by GenoMed's CEO, Dr. David Moskowitz, who is a Fellow of the American College of Physicians. The letter calls the medical community to task for the four years of "organizational silence" since Dr. Moskowitz's paper on kidney failure was first published in a peer-reviewed medical journal.

Dr. Moskowitz's paper, published in 2002, described a novel treatment approach using already existing medications but at a higher dose. If begun early enough, this approach could reverse kidney failure in white and black patients with diabetes and high blood pressure. These two diseases cause 90% of kidney failure in the US.

The Centers for Medicaid and Medicare (CMS) currently pay about $25 billion annually for kidney dialysis and transplantation. When Dr. Moskowitz briefed CMS about his paper in 2004, the Medical Director and his staff at CMS referred Dr. Moskowitz to the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Neither the NIDDK, CMS, nor any non-profit kidney association had any interest.

Publication of Dr. Moskowitz's letter in ACP Observer is the first time that a mainstream medical news magazine has carried the story.

Said Dr. Moskowitz, "In medical school, we were encouraged to find cures. I wouldn't have believed it if somebody had told me then that there was no point in finding any cures because news of the cure would just be suppressed. Yet that is exactly what has happened for the past four years."

Dr. Moskowitz continued, "Medicine, like any human endeavor, thrives on the status quo, and hates change. In the 1950s, nobody thought twice about putting polio wards and TB sanitaria out of business. But potentially eliminating 90% of a $25 billion a year industry is another thing altogether. Nowadays, nobody wants their budget cut."

Added Dr. Moskowitz, "The American College of Physicians has long been the most prestigious organization in the United States for internists. I've always been extremely proud to belong to it. I'm especially grateful for its courage in breaking the silence that has surrounded my paper for the past four years."

About GenoMed

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire1/18/2007 8:06:47 PM
   of 347
 
New Strain of Bird Flu Found in Egypt Is Resistant to Antiviral Drug

A strain of avian flu that is resistant to the antiviral drug oseltamivir has been isolated from two family members in Egypt, the World Health Organization said yesterday.

The development is potentially dangerous because oseltamivir, commonly sold under the name Tamiflu, is the chief weapon against the flu strain, H5N1, which many worry could mutate into a strain that could set off a worldwide pandemic.

The health organization emphasized that it was too early to tell whether the resistant strain had developed independently in the two patients, who were both under treatment with the drug, or whether they had picked it up from birds or from each other. The resistant strain did not spread to anyone else, including a third family member who also had avian flu.

“Given the information we have, we don’t see any broad public health implications,” said Dick Thompson, a spokesman for the organization.

Mr. Thompson was unsure which Egyptian cluster of flu infections the patients were part of. But another source said it was one in Gharbiya Province, roughly 50 miles north of Cairo, in which flu killed three people last month in a 33-member family living in one compound.

Oseltamivir-resistant strains were found in three unrelated patients in Vietnam in 2005 but did not spread.

The development “is not a big surprise, but it certainly is disheartening,” said Dr. Anne Moscona, an expert on flu treatment at Weill Cornell Medical College.

The oseltamivir-resistant strain in Egypt was susceptible to zanamivir, which is sold as Relenza, and to amantadine, which is from an older, cheaper and easier-to-use class of drugs but is not normally used as a first-line treatment because many avian flu strains are resistant to it.

The development, Dr. Moscona said, suggested that doctors might have to consider switching to a cocktail of drugs as first-line treatment, as is done with AIDS medications and sometimes with antibiotics.

Dr. Andrew T. Pavia, chairman of the pandemic influenza task force of the Infectious Diseases Society of America, said it was theoretically possible that resistant strains of the flu had developed simultaneously in two related patients, especially if they were very sick and had been treated with doses of oseltamivir that were too low.

But if one transmitted it to the other, “it would be very worrisome,” he said, because previous resistant strains had been very weak at infecting new victims.

nytimes.com

Share RecommendKeepReplyMark as Last Read


From: jmhollen2/12/2007 12:42:17 PM
   of 347
 
"African Gene" Found

Contact: David W. Moskowitz MD
CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com

ST. LOUIS—February 12, 2007—GenoMed® (OTC Pink Sheets GMED), a Next Generation Disease Management company, announced today that it has found the "African gene," responsible for the much higher incidence of diabetes, high blood pressure, and kidney failure among people of African ancestry than whites.

High blood pressure, and many other diseases, are roughly twice as common among African Americans than whites. For people with high blood pressure, kidney failure is five times more common among African Americans than whites. So blacks have 10 times more kidney failure than whites. The difference has been ascribed to the "African gene."

The "African gene," or more accurately, "African genotype," is actually a misnomer. It is not unique to Africans, but is present in every ethnic group, where it appears to cause most common diseases. (It is just more frequent among Africans). For example, it is associated with three-quarters of common diseases among whites. GenoMed has shown that knowing this "master" disease gene makes it possible to prevent kidney failure in whites, blacks, and Hispanics.

Said Dr. David Moskowitz, GenoMed's CEO, "It is appropriate that this February, Black History Month, we start trying to make kidney dialysis a thing of the past, since African Americans disproportionately make up the rolls of dialysis companies. So do other people of color: Hispanics and Native Americans have much more diabetes and kidney failure than whites."

Dr. Moskowitz continued, "The advantage of knowing the gene behind most common diseases is obvious. In this case, society is fortunate to already have safe, effective, cheap generic drugs that work against the gene. Our only problem for the past five years has been in getting the word out."

Dr. Moskowitz has published extensively on the African gene in peer-reviewed medical journals beginning in 1996.

About GenoMed

GenoMed estimates that it can already save 10% of healthcare costs and extend life by 5 years. Patients are encouraged to contact Dr. Moskowitz (dwmoskowitz@genomed.com) about joining GenoMed's Clinical Outcomes Improvement Program (COIP®).

.

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire2/13/2007 12:10:17 PM
   of 347
 
Help needed for bird flu vaccine, says official

Alvin Darlanika Soedarjo, The Jakarta Post, Jakarta

Indonesia needs foreign help to develop a bird flu vaccine for humans because local pharmaceutical companies lack the necessary technology, an official said Monday.

"Indonesia, in this case state-owned drugmaker Bio Farma, does not have the technology and expertise to create the vaccine. So far we can only offer foreign pharmaceutical companies our strain of the virus to work on," Health Ministry spokesperson Lily S. Sulistyowati told The Jakarta Post.

Lily said drugmaker Baxter approached Health Minister Siti Fadilah Supari about a year ago and offered to collaborate on a human vaccine using the Indonesian strain of the bird flu virus.

"Other companies came to us with their own vaccines using strains from other countries, such as Vietnam. We insisted that Indonesia needs a vaccine developed from our own strain.

"A vaccine derived from Indonesia's strain of the bird flu virus will be more effective when used here," she said.

Switzerland-based Baxter Healthcare SA, a subsidiary of U.S. pharmaceutical company Baxter International, has signed a memorandum of understanding with the Health Ministry to develop a human vaccine based on the Indonesian strain of the H5N1 virus.

"The vaccine is in the clinical testing phase and projected to be ready for launch in December. However, we could release the product under emergency conditions," she said.

The ministry stopped sending bird flu samples to WHO laboratories after Australian pharmaceutical company CSL announced it was developing, without Jakarta's consent, a vaccine developed from the Indonesian strain of bird flu.

Contacted separately, Indonesia Health Consumer Empowerment Foundation chairman Marius Widjajarta said the Health Ministry was right to stop sending virus samples to overseas labs.

"Indonesia has the right to stop sending out its strain because WHO was trying to develop a vaccine with commercial benefits and Indonesia would not have benefited for its efforts," Marius said.

He said the ministry should launch an investigation into WHO's actions regarding the "leakage" of Indonesian bird flu samples.

"As the hardest hit country (by bird flu), Indonesia should be careful with outside assistance because it could create a dependence on other countries," he added.

Experts still fear the virus could mutate into a more lethal version that would be easily transmitted from human to human, sparking a global pandemic that could kill millions.

thejakartapost.com

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire3/12/2007 11:39:16 AM
   of 347
 
GenoMed Prevents Sickle Cell Pain for Over a Year
GenoMed (OTC Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health™, announced today publication of a case report of a sickle cell patient whose pain has disappeared for over a year thanks to GenoMed's treatment.

The patient is a middle-aged African American woman who for years required multiple pain pills every day to tolerate the pain of her sickle cell disease. Since beginning GenoMed's trial on Dec. 22, 2005, she experienced no pain until her trial medication accidentally ran out on February 6, 2006. Said her physician, who is lead author on the case report, "Prior to this experiment, for over two years, there has not been more than a day, at least during the winter months, when she has not required some Vicodin."

Her pain ceased within a few days of resuming GenoMed's treatment in February, 2006. In June, 2006, her physician intentionally stopped GenoMed's treatment to see what would happen. The patient's pain recurred within a week. When she resumed GenoMed's treatment, her pain again stopped within a few days. She has been pain-free on GenoMed's treatment for a total of 14 months now.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Although only a single patient, she satisfied a rigorous clinical test. As long as the patient was on our treatment, her pain was gone. On two occasions, one accidental and one deliberate, our treatment was stopped. On both occasions her pain recurred promptly, only to disappear quickly after treatment was resumed. She hasn’t needed pain pills in over a year; previously she took an average of four Vicodins a day. It doesn't get much more convincing than this."

Added Dr. Moskowitz, "We'd like to see if our results hold up with additional patients. Until now, there hasn’t been effective treatment for sickle cell disease.”

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10